US · Healthcare · Biotechnology
EPS came in at -0.71 against a street estimate of -0.74 — a beat of 4.1%.
Analysts rate Precision BioSciences Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $29.40.
| Fund | Stake |
|---|---|
| Aberdeen Group PLC | 8.08% |
| Bleichroeder LP | 7.31% |
| Octagon Capital Advisors LP | 4.89% |
| BOOTHBAY FUND MANAGEMENT, LLC | 4.88% |
| BlackRock Inc | 4.25% |
| Vanguard Capital Management, LLC | 4.04% |
| Lynx1 Capital Management, LP | 3.44% |
| Driehaus Capital Management LLC | 3.43% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Precision BioSciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.